GIST: Future Treatment Landscape
Utilizing Newer TKIs to Treat GIST
GIST: Treating With Ripretinib
Safety and Efficacy of a Newer TKI for Fourth-Line GIST
The INVICTUS Trial in GIST
GIST: Third-Line Treatment Considerations
Resistance to TKI Therapies in GIST
GIST: Second-Line Treatment Options
GIST: Treatment Considerations
GIST Diagnoses and Risk of Recurrence
Case Overview: A 68-Year-Old Man With GIST
A 68-Year-Old Man With Gastrointestinal Stromal Tumor
Margaret von Mehren, MD, describes the rationale for treating a man with GIST with ripretinib as fourth-line therapy.
How Ripretinib's Mechanism of Action Works in Patients With GIST
Margaret von Mehren, MD, discusses ripretinib and how it works in patients with heavily pretreated advanced gastrointestinal stromal tumors.
2 Commerce Drive Cranbury, NJ 08512